Compugen Total Liabilities
Compugen total liabilities. Based on the latest financial reports, Compugen (CGEN) has total liabilities worth ILA49.25 Million ILA (≈ $132.04K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Compugen (CGEN) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Compugen (1999–2025)
Total liabilities of Compugen from 1999 to 2025. This chart illustrates how Compugen's total liabilities have evolved over time, based on quarterly financial data. Explore Compugen long-term investment intensity to see how much of total assets are deployed in long-term investments.
Compugen Competitors by Total Liabilities
The table below lists competitors of Compugen ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Millennial Potash Corp.
V:MLP
|
Canada | CA$1.39 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩184.63 Billion |
|
Kuen Chaang Uppertech
TWO:6265
|
Taiwan | NT$299.75 Million |
|
Inesa Intelligent Tech Inc B
SHG:900901
|
China | $2.89 Billion |
|
Home Center Holdings Co.Ltd
KQ:060560
|
Korea | ₩293.88 Billion |
|
Curexo Inc
KQ:060280
|
Korea | ₩9.36 Billion |
|
DCX Systems Limited
NSE:DCXINDIA
|
India | Rs-15.13 Billion |
|
UmweltBank AG
XETRA:UBK
|
Germany | €-417.13 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Compugen's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Compugen.
Liquidity & Leverage Metrics
Compugen Total Liabilities Ratios Explained
Compugen total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Compugen's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Compugen (1999–2025)
The table below shows the annual total liabilities of Compugen from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA54.14 Million ≈ $145.15K |
-9.88% |
| 2024-12-31 | ILA60.08 Million ≈ $161.08K |
+7.72% |
| 2023-12-31 | ILA55.77 Million ≈ $149.53K |
+238.11% |
| 2022-12-31 | ILA16.50 Million ≈ $44.23K |
-35.23% |
| 2021-12-31 | ILA25.47 Million ≈ $68.28K |
+37.42% |
| 2020-12-31 | ILA18.53 Million ≈ $49.69K |
+20.02% |
| 2019-12-31 | ILA15.44 Million ≈ $41.40K |
-3.11% |
| 2018-12-31 | ILA15.94 Million ≈ $42.73K |
+68.66% |
| 2017-12-31 | ILA9.45 Million ≈ $25.33K |
+24.00% |
| 2016-12-31 | ILA7.62 Million ≈ $20.43K |
-19.02% |
| 2015-12-31 | ILA9.41 Million ≈ $25.23K |
+6.09% |
| 2014-12-31 | ILA8.87 Million ≈ $23.78K |
-64.27% |
| 2013-12-31 | ILA24.82 Million ≈ $66.55K |
+120.90% |
| 2012-12-31 | ILA11.24 Million ≈ $30.13K |
+18.28% |
| 2011-12-31 | ILA9.50 Million ≈ $25.47K |
+16.24% |
| 2010-12-31 | ILA8.17 Million ≈ $21.91K |
+193.25% |
| 2009-12-31 | ILA2.79 Million ≈ $7.47K |
-34.28% |
| 2008-12-31 | ILA4.24 Million ≈ $11.37K |
-3.20% |
| 2007-12-31 | ILA4.38 Million ≈ $11.75K |
-14.40% |
| 2006-12-31 | ILA5.12 Million ≈ $13.72K |
-12.63% |
| 2005-12-31 | ILA5.86 Million ≈ $15.71K |
+1.23% |
| 2004-12-31 | ILA5.79 Million ≈ $15.51K |
-25.02% |
| 2003-12-31 | ILA7.72 Million ≈ $20.69K |
-7.86% |
| 2002-12-31 | ILA8.38 Million ≈ $22.46K |
+15.90% |
| 2001-12-31 | ILA7.23 Million ≈ $19.38K |
+34.78% |
| 2000-12-31 | ILA5.36 Million ≈ $14.38K |
+96.34% |
| 1999-12-31 | ILA2.73 Million ≈ $7.32K |
-- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more